EEG Study Reveals Insights into Full Spectrum Cannabis Effects
PAX, a leading global cannabis brand, has collaborated with Canadian neurotechnology company Zentrela to conduct an EEG-based study on the psychoactive effects of cannabis. The study compared two inhalable cannabis products, focusing on the faster onset and increased psychoactive experience associated with full spectrum products. The presence of additional compounds, such as phytocannabinoids and terpenes, in full spectrum products was found to contribute to these effects. The research aims to provide consumers with data-driven insights to make more informed decisions when purchasing and consuming cannabis products.
Challenging the Focus on THC Percentage
The study challenges the common belief that THC percentage alone determines the psychoactive effects of cannabis. Brian Witlin, VP of Product Development at PAX, emphasizes the importance of understanding the full range of terpenes and cannabinoids in achieving a more profound cannabis experience. By expanding scientific research and knowledge, PAX aims to shift the focus away from THC percentage as the sole indicator of expected effects.
Advancing Cannabis Research and Consumer Understanding
Israel Gasperin, founder and CEO of Zentrela, shares the mission to enhance consumer understanding of cannabis experiences. The collaboration with PAX allows for innovative research techniques and a commitment to scientific advancement in studying cannabis effects. By providing accurate and objective information, Zentrela aims to empower consumers to make informed decisions about cannabis consumption.
In conclusion, the EEG study conducted by PAX and Zentrela sheds light on the effects of full spectrum cannabis products. The findings challenge the emphasis on THC percentage and highlight the importance of additional compounds in achieving a more profound psychoactive experience. This research contributes to advancing cannabis research and enhancing consumer understanding of cannabis effects.
Hot Take: The Impact of Full Spectrum Cannabis Research on New Businesses
The recent EEG-based study conducted by PAX and Zentrela, focusing on the psychoactive effects of full spectrum cannabis products, provides valuable insights for new businesses in the cannabis industry. The study's findings challenge the traditional focus on THC percentage and underscore the importance of other compounds, such as phytocannabinoids and terpenes, in contributing to the overall cannabis experience.
Reframing the Cannabis Experience
For new businesses, this research offers a fresh perspective on how to approach product development and marketing. The emphasis on the full range of terpenes and cannabinoids, as highlighted by Brian Witlin, VP of Product Development at PAX, suggests that businesses should not solely focus on THC percentage when developing and promoting their products. Instead, a more comprehensive understanding of the cannabis experience can be achieved by considering the full spectrum of compounds present in the product.
Empowering Consumers through Research and Education
Furthermore, the commitment of PAX and Zentrela to advancing cannabis research and enhancing consumer understanding can serve as a model for new businesses. By investing in innovative research techniques and providing accurate and objective information, businesses can empower consumers to make informed decisions, thereby building trust and fostering customer loyalty.
In conclusion, the insights gained from the PAX and Zentrela study offer new businesses in the cannabis industry a fresh perspective on product development and consumer education. By embracing a more comprehensive understanding of the cannabis experience and empowering consumers with accurate information, new businesses can position themselves for success in this evolving market.